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Abstract
Introduction: Regional citrate anticoagulation (RCA) is a valid option in patients at high risk of bleeding who are
undergoing continuous renal replacement therapy (CRRT). The aim of this study was to evaluate, in critically ill
patients with severe acute kidney injury following cardiac surgery, the efficacy and safety of RCA-continuous veno-
venous hemofiltration (CVVH) using a low concentration citrate solution.
Methods: In high bleeding-risk cardiac surgery patients, we adopted, as an alternative to heparin or no
anticoagulation, RCA-CVVH using a 12 mmol/l citrate solution. For RCA-CVVH settings, we developed a
mathematical model to roughly estimate citrate load and calcium loss. In order to minimize calcium chloride
supplementation, a calcium-containing solution was used as post-dilution replacement fluid.
Statistical analysis was performed using the Student t-test or analysis of variance (ANOVA) with post-hoc tests,
Wilcoxon or Kruskal-Wallis tests for non-parametric analysis, and Kaplan-Meier survival analysis with Log Rank test.
Results: Thirty-three patients (age 70.8 ± 9.5, Sequential Organ Failure Assessment (SOFA) score 13.9 ± 2.5) were
switched to RCA-CVVH from no anticoagulation CRRT. Among them, 16 patients had been previously switched
from heparin to no anticoagulation because of bleeding or heparin-related complications. RCA-CVVH filter life (49.8
± 35.4 hours, median 41, 152 circuits) was significantly longer (P < 0.0001) when compared with heparin (30.6 ±
24.3 hours, median 22, 73 circuits) or no anticoagulation (25.7 ± 21.2 hours, median 20, 77 circuits). Target circuit
and systemic Ca++ were easily maintained (0.37 ± 0.09 and 1.18 ± 0.13 mmol/l), while the persistence of a mild
metabolic acidosis required bicarbonate supplementation (5.8 ± 5.9 mmol/hours) in 27 patients. The probability of
circuit running at 24, 48, 72 hours was higher during RCA-CVVH (P < 0.0001), with a lower discrepancy between
delivered and prescribed CRRT dose (P < 0.0001). RCA was associated with a lower transfusion rate (P < 0.02).
Platelet count (P = 0.012) and antithrombin III activity (P = 0.004) increased throughout RCA-CVVH, reducing the
need for supplementation.
Conclusions: RCA safely prolonged filter life while decreasing CRRT downtime, transfusion rates and
supplementation needs for antithrombin III and platelets. In cardiac surgery patients with severe multiple organ
dysfunction syndrome, the adoption of a 12 mmol/l citrate solution may provide a suboptimal buffers supply,
easily overwhelmed by bicarbonate supplementation.
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Introduction
Continuous renal replacement therapies (CRRT) are
widely adopted in the management of severe acute kidney
injury (AKI) in critically ill patients with hemodynamic
instability and multiple organ dysfunction syndrome
(MODS) [1-3]. A potential drawback of CRRT is the
need for prolonged anticoagulation to prevent clotting of
the extracorporeal circuit [4]. Heparin is the standard
choice but the incidence of bleeding is reported in up to
30% of renal replacement therapies [5-8] and it is well
known that bleeding complications are associated with
an increased risk of mortality in AKI patients [9]. Bleed-
ing risk and/or the development of heparin-induced
thrombocytopenia contributed to an increasing interest
in alternative strategies [10-13]. Among them, regional
citrate anticoagulation (RCA) seems to be a valid option
in patients with a high bleeding risk [12,13]. Citrate pro-
vides anticoagulation by a process referred to as chelation
of ionized calcium [12]. The depletion of ionized calcium
interrupts clotting cascade activation at several stages
[14]. Since citrate is a small molecule (MW 258 Da), the
calcium-citrate complex is easily removed by diffusion
and/or convection and systemic calcium infusion is thus
required to replace the calcium lost in the effluent [15].
The citrate metabolic load derives from the balance
between the prescribed citrate dose and the amount of
citrate removed by filtration and/or dialysis [15]. Citrate
returning to the patient is rapidly metabolized in bicarbo-
nate mainly by the liver, but also by skeletal muscle and
the renal cortex [12]. Reported issues with RCA include
metabolic alkalosis and acidosis, hyper- and hyponatre-
mia and hypocalcemia, but these complications are
uncommon with an accurate monitoring of the proce-
dure [12,16]. Known RCA protocols are characterized by
variability in CRRT modality, citrate metabolic load and
composition of citrate and CRRT solutions, in many
cases customized and hospital pharmacy-formulated [17].
However, the availability of dedicated commercial solu-
tions could help simplify protocols allowing to improve
safety and to expand the use of RCA.
The aim of this study was to evaluate prospectively
the efficacy and safety of a simplified RCA protocol
adopting a low concentration citrate solution in critically
ill patients with a high bleeding risk undergoing CRRT
for AKI following cardiac surgery.
Materials and methods
Starting in May 2008 we adopted RCA as an alternative to
heparin or no anticoagulation (no-AC) in patients with a
high risk of bleeding who were undergoing CRRT due to
AKI following cardiac surgery. The present observational
study was in agreement with the Declaration of Helsinki
and written informed consent was obtained from either
the patient or a close relative. Ethics Committee approval
was not required for this observational study because all
data reported, as well as anticoagulation method assign-
ment, were part of our routine medical procedures and
guidelines.
CRRT was performed using the Prismaflex system
(Gambro Lundia AB, Lund, Sweden). Acrylonitrile
sodium-metallyl-sulfonate (AN69ST) or polyarylethersul-
fone (PAES) hemofilter (Prismaflex ST100, 1 m2, or HF
1000, 1.15 m2, Gambro, Meyzieu, France) were used. A
conventional heparin protocol (starting infusion 5 IU/kg/
hour, adjusted to meet the target activated partial throm-
boplastin time (aPTT) ratio of approximately 1.5) was
applied only to patients without active bleeding. Patients
who fulfilled or developed any of the following criteria,
defining a high bleeding risk, were assigned or switched to
a no-AC regimen: platelet count < 50000/μl or heparin-
induced thrombocytopenia, spontaneous or heparin asso-
ciated bleeding, basal aPTT > 45 seconds, and surgery in
the last 48 hours [18]. Filter clotting within 24 hours run-
ning time was considered as a criterion to switch from no-
AC to RCA.
Heparin and no-AC CRRT were performed in pre-dilu-
tion continuous veno-venous hemodiafiltration
(CVVHDF) using a bicarbonate solution as dialysate and
replacement fluid (HCO3
- 32, Ca++ 1.75, Mg++ 0.5, K+ 2,
Na+ 140, Cl- 111.5 mmol/l; Prismasol 2, Gambro, Sondalo,
Italy) with a suggested dialysis dose corrected for pre-dilu-
tion (correction factor = blood flow rate/(blood flow rate
+ pre-dilution infusion rate)) of at least 25 ml/kg/hour.
RCA was performed in CVVH modality (RCA-CVVH)
using a pre-dilution citrate solution (trisodium citrate 10,
citric acid 2, Na+ 136 mmol/l, Cl- 106 mmol/l; Prismoci-
trate 10/2, Gambro, Sondalo, Italy) and a post-dilution
bicarbonate solution (Prismasol 2) (Figure 1).
In relation to blood flow rate (Qb), citrate solution rate
was set to meet a circuit citrate concentration of 3 mmol/l
and modified, if needed, to obtain circuit ionized calcium
(c-Ca++) < 0.40 mmol/l (post-filter sample). Post-dilution
bicarbonate solution rate was adjusted to achieve a total
dialysis dose of 30 ml/kg/hour with the aim of ensuring a
prescribed dialysis dose, corrected for pre-dilution, of at
least 25 ml/kg/hour. Calcium chloride (CaCl2 10%) was
infused in a separate central venous line to maintain sys-
temic ionized calcium (s-Ca++) in the normal range (1.1 to
1.25 mmol/l). During RCA-CVVH, magnesium sulphate
was infused as needed to avoid hypomagnesemia. To facil-
itate the initial RCA-CVVH settings, we used a mathema-
tical model to roughly estimate metabolic citrate load,
buffers balance (citrate and bicarbonate) and effluent
calcium loss. The model, developed with the FileMaker
database (FileMaker Inc, Santa Clara, CA, USA) and com-
patible with many portable devices, allowed easy para-
meter calculation at the patient’s bedside. Assumed
sieving coefficients (SC) were 0.9 for citrate, 1.0 for ionized
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calcium and bicarbonate. The input fields were as follows:
Qb (ml/minute), citrate solution concentration (mmol/l),
citrate solution flow rate (l/hour), bicarbonate and ionized
calcium replacement solution concentration (mmol/l),
post-dilution flow rate (l/hour), patient’s bicarbonate and
ionized calcium (mmol/l), patient’s hematocrit (%) and
serum protein (g/dl), net ultrafiltration rate (l/hour). Cal-
culated output fields (corrected for pre-dilution when
appropriate) were as follows: pre-filter estimated citrate
blood concentration (mmol/l) calculated in plasma water
((citrate solution concentration x citrate flow rate)/(citrate
flow rate + plasma water flow rate)), total effluent rate (l/
hour), filtration fraction (%), estimated citrate metabolic
load (mmol/hour) ((citrate solution concentration x citrate
flow rate) - (effluent rate x estimated citrate blood concen-
tration x SC)), CVVH buffers and calcium balance (mmol),
and suggested CaCl2 infusion rate (ml/hour).
Serum electrolytes, including total Ca, P, K, Mg, coa-
gulation parameters and complete blood count were
assessed daily. Acid-base parameters and electrolytes (K
+, Ca++) were measured by an arterial blood gases analy-
zer (GEM Premiere 4000, Instrumentation Laboratory
UK Ltd, Warrington, UK) at least every four hours.
Potassium and phosphate loss with CRRT was replaced
with potassium chloride and sodium phosphate infusion.
Total calcium/s-Ca++ ratio (Calcium Ratio) > 2.5 was
considered an indirect sign of citrate accumulation [19].
Reasons for stopping CRRT have been accurately
reported after evaluation of monitor events and pressure
alarms, recorded on the Prismaflex memory card. CRRT
interruption due to coagulation was defined as an overt
sign of circuit clotting or as a 100% increase of filter
drop pressure (the difference between pre-filter and
post-filter hydrostatic pressure). CRRT interruption for
clinical reasons (that is, for evaluation of renal function
recovery, modification of CRRT schedule during the
recovery phase of AKI, patient mobilization, and so on),
unrelated to circuit clotting, was classified and reported
as scheduled CRRT stopping. Regardless of the anticoa-
gulation modality, blood units transfused per day were
recorded throughout the CRRT period.
Statistical analysis
Data are reported as mean ± standard deviation (m ± SD).
Statistical analysis for continuous variables was made
using the Student t-test or analysis of variance (ANOVA)
with Bonferroni post-hoc test. Non-parametric tests were
performed using the Wilcoxon signed-rank test for related
samples or Kruskal-Wallis test for independent samples.
Circuit lifetime was evaluated with Kaplan-Meier survival
Figure 1 Regional citrate anticoagulation in pre-post dilution CVVH modality with a calcium-containing replacement solution. CVVH,
continuous veno-venous hemofiltration.
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analysis and survival curves distribution was compared
with the Log Rank (Mantel-Cox) test. All tests were two-
sided (significance level 5%). IBM SPSS statistical (19.0,
SPSS Inc., USA) was used for all analyses.
Results
Thirty-three high-bleeding-risk patients underwent RCA-
CVVH due to AKI following cardiac surgery. In all cases
RCA-CVVH was started because of early circuit clotting
(< 24 hours) with no-AC CRRT. Among them, 16 patients
had been previously switched from heparin CRRT to no-
AC because of bleeding or heparin-related complications.
Clinical characteristics of the patients at the time of start-
ing CRRT and RCA-CVVH initial parameters are listed in
Table 1. During RCA-CVVH, c-Ca++ post-filter values,
almost constantly < 0.40 mmol/l (0.37 ± 0.09, median
0.37), confirmed the adequacy of citrate flow rate in most
cases (149/152 sessions) while an increase of the initial
citrate infusion rate was required, for c-Ca++ recurrently >
0.4 mmol/l, in only 3/152 sessions. Systemic Ca++ was
easily maintained in the normal range with few modifica-
tions of CaCl2 flow rate (1 to 2 within 24 hours). CaCl2
was infused at a mean rate of 2.38 ± 0.77 mmol/hour,
which is equivalent to an amount of calcium element of
2.3 ± 0.7 g/day. Mean s-Ca++ was 1.18 ± 0.13 mmol/l
(median 1.18). No episodes of clinically relevant hypocal-
cemia or hypercalcemia were observed. Mean Calcium
Ratio was 1.98 ± 0.2 (median 1.96, range 1.48 to 3.08). In
one patient with cardiogenic shock, RCA-CVVH was
stopped due to an indirect sign of citrate accumulation
(Calcium Ratio = 3.08).
One hundred fifty-two circuits were used in RCA-
CVVH with a filter life of 49.8 ± 35.4 hours (median 41,
range 4.5 to 163, total 7,570) (Table 2). Excluding sched-
uled CRRT stopping, circuit lifetime was 52.2 ± 36.1 hours
(median 48). Before starting RCA, we used 73 heparin cir-
cuits in 16 patients and 77 no-AC circuits in 33 patients
with a filter life of 30.6 ± 24.3 hours (median 22, range
3 to 96, total 2,233) and 25.7 ± 21.2 hours (median 20,
range 3 to 94, total 1,980), respectively (Table 2), in both
cases significantly shorter than RCA-CVVH (P = 0.0001).
CRRT stopping causes and circuits running at 24, 48,
72 hours are reported in Table 2. RCA-CVVH did not
stop in any case for filter clotting and filter drop pressure
Table 1 Clinical characteristics of the patients at the time of starting CRRT and RCA-CVVH initial parameters.
Number = 33 (24 men, 9 women)
Age (years) 70.8 ± 9.5 (range 46 to 85)
Creatinine (mg/dl) 2.5 ± 0.9
Blood urea nitrogen (mg/dl) 54.3 ± 26.2
Mean arterial pressure (mmHg) 72.5 ± 10.2
Oliguric AKIa 94%
Mechanical ventilation 100%
Total parenteral or enteral nutrition 100%
Use of vasopressors or inotropes 75.8%
APACHE II score 32.1 ± 4.6
SOFA score 13.9 ± 2.5
MELD score 18.7 ± 4.7
Bilirubin (mg/dl) 1.68 ± 1.98
Cardiovascular surgery:
Coronary artery bypass grafting 33.3%
Coronary artery bypass grafting + valvular surgery 27.3%
Ascending aorta replacement 24.2%
Valvular surgery 15.2%
RCA-CVVH initial parametersb
Prescribed dialysis dose, corrected for pre-dilution (ml/kg/hour) 28.1 ± 2.9
Blood flow rate (ml/minute) 135.7 ± 14.6
Pre-dilution citrate solution flow rate (l/hour) 1.69 ± 0.23
Post-dilution bicarbonate solution flow rate (l/hour) 0.77 ± 0.17
Calcium chloride 10% (mmol/hour) 2.38 ± 0.77
Citrate infusion rate (mmol/hour) 20.3 ± 2.8
Estimated citrate load (mmol/hour) 11.5 ± 2
Data are expressed as mean ± SD or percentage. aAccording to AKIN criteria (Crit Care 2007; 11:R31). bData derived from the first RCA-CVVH session for each
patient. AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; APACHE, Acute Physiology and Chronic Health Evaluation; CRRT, continuous renal
replacement therapy; MELD, Model for End-Stage Liver Disease; RCA-CVVH, regional citrate anticoagulation-continuous veno-venous hemofiltration; SD, standard
deviation; SOFA, Sequential Organ Failure Assessment.
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showed slight increments over the course of RCA-CVVH
sessions (Δ filter drop pressure 11.8% ± 4.7% after
48 hours running time, median 7.4%). Only one circuit
was replaced after 91 hours due to the presence of clots in
the venous drip chamber. For each anticoagulation modal-
ity, Kaplan-Meier curves of circuit lifetime probability,
derived from analysis of scheduled and unscheduled
CRRT interruptions due to any cause, are displayed in
Figure 2. The discrepancy between delivered versus
prescribed CRRT dose, calculated as Δ-dose, was -4.7%
during RCA-CVVH, significantly lower than heparin and
no-AC modalities (-13% and -12.7% respectively, P <
0.0001). Prescribed dialysis dose, corrected for pre-
dilution, was comparable among different anticoagulation
modalities (Table 2). Delivered dialysis dose during RCA-
CVVH (25.6 ± 4.9 ml/kg/hour) was significantly higher
than that achieved with heparin (23.7 ± 7.2 ml/kg/hour,
P = 0.016) and no-AC (23.1 ± 8 ml/kg/hour, P < 0.001)
modalities (Table 2). During RCA-CVVH circuits con-
sumption was 0.48/day, significantly lower if compared
with heparin (0.78/day) or no-AC (0.93/day) (P < 0.0001).
The main metabolic and electrolyte parameters for the
first four days and for the last day of RCA-CVVH are
shown in Table 3.
In 27 out of 33 patients, the persistence of a mild
metabolic acidosis during RCA-CVVH, unrelated to
citrate accumulation, required additional NaHCO3 infu-
sion (5.8 ± 5.9 mmol/hour). In all patients Mg++ levels
were corrected with magnesium sulphate continuous
infusion (3 g/day).
Platelet count and antithrombin III (AT-III) activity
increased throughout RCA days (P = 0.012 and P =
0.004, respectively) allowing us to stop supplementation
if previously required (Figure 3). During RCA-CVVH no
patients had bleeding complications and the transfusion
rate was lower compared with heparin (0.29 versus 0.62,
P = 0.017) or no-AC (0.29 versus 0.64 blood units/day,
P = 0.019) (Figure 3). Thirty-day survival was 66.7%
while survival at discharge from the hospital was 45.5%.
At the time of discharge, renal function recovery, allow-
ing the cessation of RRT, was observed in 13 out of 15
survivors (86.7%).
Discussion
Among the key problems of CRRT, the need for pro-
longed anticoagulation is its most important drawback
[4]. The incidence of bleeding complications during
RRT is extremely variable among different patient popu-
lations but, in any case, the incidence of major bleeding
is not infrequent and cannot be neglected. Therefore,
alternative methods of anticoagulation should be more
widely adopted and, among potential alternatives to sys-
temic anticoagulation, RCA is the most promising.
Indeed, several studies reported better filter survival
and/or fewer bleeding events with RCA, compared to
unfractioned heparin [20-23]. A recent meta-analysis,
Table 2 Circuit lifetime, CRRT stopping causes and prescribed versus delivered dialysis dose according to different
anticoagulation modalities.
RCA (n = 152) Heparin (n = 73) No AC (n = 77)
CIRCUIT LIFETIME
Mean ± SD (hours) 49.8 ± 35.4*** 30.6 ± 24.3 25.7 ± 21.2
Median (hours) 41 22 20
> 24 hours 74% 45% 40%
> 48 hours 41% 25% 14%
> 72 hours 27% 12% 5%
CRRT STOPPING CAUSES
CVC malfunction 34.9% 17.8% 15.6%
Alarm handling/technical issues 23.7% 12.3% 2.6%
Scheduled 19.7% 0% 1.3%
Medical procedures 13.8% 2.8% 3.9%
Clotting 0% 61.6% 68.8%
Unidentified 7.9% 5.5% 7.8%
DIALYSIS DOSEa
Prescribed dose (ml/kg/hour) 26.8 ± 3.8 27.3 ± 4.7 26.6 ± 7.1
Delivered dose (ml/kg/hour) 25.6 ± 4.9** 23.7 ± 7.2 23.1 ± 8
Delta dose (%) 4.7 ± 12.1*** 13 ± 20.5 12.7 ± 19.1
Data are expressed as mean ± SD or percentage. aCorrected for predilution. Statistical comparison among different anticoagulation modalities: ANOVA with
Bonferroni post-hoc test. ***P < 0.0001; **P < 0.02. AC, anticoagulation; ANOVA, analysis of variance; CRRT, continuous renal replacement therapy; CVC, central
venous catheter; n, number; RCA, regional citrate anticoagulation; SD, standard deviation.
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Figure 2 Kaplan-Meier curves of circuit lifetime probability, according to different anticoagulation modalities, derived from analysis of
scheduled and unscheduled CRRT stopping for any cause. Scheduled CRRT stopping has been censored. Survival curves distribution has
been compared with Log Rank (Mantel-Cox) test (P < 0.0001). CRRT, continuous renal replacement therapy.
Table 3 Main metabolic and electrolyte parameters throughout RCA-CVVH days.
Days on RCA
1 2 3 4 Last day
Systemic Ca++ (mmol/l) 1.2 (1.09-1.36) 1.2 (1.14-1.25) 1.19 (1.15-1.24) 1.16 (1.12-1.26) 1.19 (1.13-1.24)
Circuit Ca++ (mmol/l) 0.39 (0.33-0.43) 0.37 (0.31-0.4) 0.32 (0.28-0.37)** 0.35 (0.31-0.39) 0.34 (0.32-0.39)
Systemic sodium (mmol/l) 136 (134-139.2) 135 (133-138) 134 (132-138)* 134 (131.7-136)* 135 (134-136)
Estimated citrate load (mmol/hour) 11.3 (10.1-12.4) 11.3 (10.2-12.3) 11.3 (10.1-12.5) 11.3 (10.2-12.5) 10.7 (10.1-11.9)
Calcium Ratio 1.88 (1.78-2.04) 1.96 (1.87-2.04) 1.96 (1.84-2.1) 1.92 (1.82-2.1) 2 (1.89-2.08)
pH (units) 7.4 (7.35-7.43) 7.4 (7.36-7.42) 7.4 (7.34-7.43) 7.4 (7.35-7.43) 7.41 (7.37-7.43)
Systemic bicarbonates (mmol/l) 22.9 (20.6-23.9) 22 (20.9-22.8) 22 (20.7-23.2) 21.4 (20.2-23.3) 22 (20.4-23.2)
Base excess -3 (-4.7 to -1.1) -3.2 (-3.8 to -2) -3.1 (-4.1 to -2) -3 (-3.5 to -1.6) -2.5 (-4 to -1)
Systemic lactate (mmol/l) 1.3 (1-1.8) 1.2 (0.9-1.5) 1.05 (0.8-1.25) 1 (0.9-1.3) 1.1 (0.7-1.65)
Data are expressed as median (interquartile range). All points of considered parameters were not significant, except for time day 3 versus day 1 of circuit Ca++ (**
P < 0.02) and for time day 3 and 4 versus day 1 of systemic sodium (* P < 0.05). RCA-CVVH, regional citrate anticoagulation-continuous veno-venous
hemofiltration.
Morabito et al. Critical Care 2012, 16:R111
http://ccforum.com/content/16/3/R111
Page 6 of 10
including six randomized studies, confirmed that RCA
was able to prolong circuit life and to reduce the risk of
bleeding with a pooled risk ratio of 0.28 in comparison
to the control group [24]. The aim of the present study
was to evaluate the efficacy and safety of a simplified
protocol of RCA-CVVH in patients undergoing CRRT
due to AKI following cardiac surgery. In this selected
population, the anticoagulation strategy was intended to
reduce bleeding complications maintaining, at the same
time, an adequate circuit lifespan to minimize downtime
periods. All patients received RCA-CVVH because of a
high risk of bleeding, contraindicating heparin, or
because of heparin-related complications (bleeding,
thrombocytopenia). In any case, RCA-CVVH was started
after an attempt to perform CRRT without anticoagula-
tion. In this regard, in the Acute Renal Failure Trial
Network study more than 50% of CVVHDF treatments
were performed without anticoagulation [25]. However,
in the same study the prescribed dialysis dose was, in
the best case, delivered in only 70% of the patients and
it is well known that filter clotting, together with vascu-
lar access malfunction, is the main cause of discrepancy
between the prescribed and delivered dose in CRRT
[25]. The assessment of any difference in filter lifespan
and CRRT downtime was a secondary endpoint of our
observational study, with consequent limitations, mainly
related to the comparison of anticoagulation modalities
at different stages in the course of critical illness and to
the recruitment to switch to RCA-CVVH after failure of
no-AC. In any case, taking account of these limitations,
the switch from no-AC to RCA-CVVH allowed us to
prolong filter life significantly and to minimize treat-
ment downtime. Indeed, the delivered dose in RCA-
CVVH was about 95% of the prescribed dose, with a
dose discrepancy significantly lower than that observed
during heparin or no-AC CRRT. Furthermore, RCA-
CVVH was associated with a significantly lower need for
filter set replacement. Although cost analysis was not
performed in our study, it has been reported that a
longer filter life during RCA could play a role in mini-
mizing the total CRRT cost compared to heparin antic-
oagulation [26,27]. On the other hand, indirect costs,
such as platelet and red cell transfusions, as well as AT-
III supplementation, can also be taken into account for
cost analysis. In the present study, platelet count and
AT-III activity increased throughout the days of RCA
Figure 3 Platelet count and antithrombin III throughout days of RCA-CVVH (comparison versus day 1, ** P < 0.02; *** P < 0.005). Data
are expressed as median, interquartile range (q1 to q3), minimum (min), maximum (max). On the bottom, transfusion rate (units/day) during
RCA-CVVH days and comparison of transfusion rates among different anticoagulation modalities. RCA-CVVH, regional citrate anticoagulation-
continuous veno-venous hemofiltration.
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allowing us to stop supplementation where it was for-
merly required. Moreover, as already reported by other
authors [20-23], no patients had bleeding complications
during RCA-CVVH and the transfusion rate was signifi-
cantly lower if compared with the other anticoagulation
modalities. Regarding reasons for stopping CRRT, Kut-
sogiannis et al. reported, in 30 patients randomly
assigned to heparin or citrate, a less frequent occurrence
of circuit clotting during RCA (16.7% versus 53.5%, P =
0.002) [21]. In our study, RCA-CVVH did not stop in
any case because of filter clotting, as confirmed by the
stability of filter drop pressure recorded throughout the
circuit running time.
Regarding a potential impact upon survival, most rando-
mized studies comparing RCA with heparin anticoagula-
tion are too small to demonstrate a difference in clinical
outcome [13]. However, a recent study including 200 criti-
cally ill patients receiving CRRT, randomly assigned to
low molecular weight heparin (LMWH) (nadroparin) or
RCA, showed an unexpected 15% absolute increase in
three-month survival, seemingly not justified by a lower
incidence of bleeding [28]. In the same study, post-hoc
analysis showed that RCA may be particularly beneficial in
specific clinical conditions (surgery, sepsis, severe MODS,
younger age). To explain these findings, it has been
hypothesized that local hypocalcemia during RCA might
reduce the release of inflammatory mediators from cells
adhered to the hemofilter membrane [28]. Although the
present study was not aimed at comparing survival among
different anticoagulation strategies, in our selected popula-
tion of cardiac surgery patients, receiving RCA-CVVH for
AKI and severe MODS, survival at the time of discharge
was about 45%, comparable to that reported by Oude-
mans-van Straaten in the citrate group [28].
Despite several reports about the efficacy and safety of
RCA, the diffusion of this method of anticoagulation
appears relatively limited, ranging from about 10% (B.E.S.
T. kidney survey) [1] to 20% (Acute Renal Failure Trial
Network study) [25] of CRRT treatments. Probably,
among different reasons, RCA has not yet gained wide-
spread application because of the complexity of early pro-
tocols and because of concerns about metabolic or
electrolyte complications. With the aim of simplifying
RCA handling, we adopted a protocol of pre-post dilution
CVVH in which citrate was used as the anticoagulation
solution as well as pre-dilution replacement fluid. The
adoption of the CVVH modality allowed us to use only
two different solutions (citrate + conventional replacement
fluid) and to avoid zero calcium dialysate. Furthermore, to
reach the prescribed dialysis dose and to minimize the
amount of calcium supplementation, we introduced the
novelty of adopting a calcium-containing post-dilution
replacement fluid (1.75 mmol/l). Indeed, the amount of
CaCl2 infused in a separate line was lower than that
reported elsewhere [20,29], and the use of a calcium-con-
taining post-dilution replacement fluid was not associated
with drip chamber clotting in the venous line. Moreover,
the use of a mathematical model to roughly estimate citra-
temia and calcium balance allowed us to easily calculate
the initial setting of the RCA-CVVH parameters minimiz-
ing nurse workload related to the need for additional
interventions. In particular, estimation of the initial setting
of the CaCl2 infusion required only one or two adjust-
ments in the first 24 hours of each session and resulted in
the avoidance of complications related to hypo- or hyper-
calcemia. Mathematical models, developed to calculate the
volume of citrate infusion required to achieve the target
Ca++ in the extracorporeal circuit and to restore the total
calcium level have been recently proposed and validated
[30,31]. Regarding metabolic or electrolyte complications,
old RCA protocols were characterized by extreme variabil-
ity in the citrate solution composition, in most cases
requiring the adoption of customized low sodium concen-
tration dialysate or replacement fluid [17,32]. However,
alkalosis and hypernatremia, although representing poten-
tial RCA complications, are rarely observed with the
appropriate combination of citrate and dialysate (and/or
replacement fluid) solutions. In particular, alkalosis may
be observed only in the case of imbalance between the
supply of buffers (citrate and bicarbonate) and citrate/
bicarbonate removal by ultrafiltration and/or dialysis
(inappropriate combination of solutions and/or inadequate
RCA-CRRT parameters setting). In this regard, strategies
for the prevention of citrate accumulation should be tar-
geted to decrease citrate administration, through the use
of a low blood flow rate, and to increase citrate clearance,
through optimization of convective and/or diffusive dialy-
sis dose. Mariano et al. showed that a careful RCA strat-
egy, targeted to reduce citrate load, ensured metabolic
tolerance also in severe septic shock patients [33]. The
protocol adopted in the present study provided an ade-
quate RCA without electrolyte derangements. Further-
more, the citrate load was below the lowest range reported
until now by other authors (33) and allowed us to prevent
citrate accumulation in all but one patient. However, on
the other side, the low amount of citrate delivered to the
patient was associated, in most cases, with a suboptimal
buffers supply. As a consequence, despite optimization of
CVVH parameters (that is, citrate infusion rate and/or
post-dilution bicarbonate flow rate) the persistence of a
mild metabolic acidosis required additional bicarbonate
infusion. Comparable findings, regarding the need for
additional bicarbonate, have been reported by Hetzel per-
forming CVVH with a 13 mmol/l citrate solution [23].
Therefore, adopting a very low concentration citrate solu-
tion requires further refinements to optimize the buffers
balance. Our purpose was to evaluate the use of a more
concentrated bicarbonate replacement fluid in order to
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customize the buffers supply in individual patients,
through the modulation of the post-dilution flow rate
according to their acid-base status. On the other hand, the
use of a higher citrate concentration (18 mmol/l), reported
by Tolwani [34], provided an appropriate acid-base bal-
ance but required, to avoid alkalosis, a lower than usual
dialysate bicarbonate concentration (25 mmol/l). Morgera
et al., performing CVVHDF with a high concentration
citrate solution (136 mmol/l), combined with a low
sodium and bicarbonate dialysate (133 and 20 mmol/l,
respectively), were able to modulate acid-base status by
modifying either the dialysate or the blood flow rate [35].
Conclusions
The regional citrate anticoagulation protocol adopted in
our study appeared safe, easy to apply and effective in
preventing circuit clotting, thus minimizing CRRT down-
time in critically ill cardiac surgery patients with AKI and
MODS. Furthermore, RCA allowed us to ensure an ade-
quate filter life and to decrease the transfusion rate, as
well as the supplementation need for AT-III and plate-
lets, without bleeding complications. In our opinion,
RCA should be worthy of more consideration as the first
choice anticoagulation modality in critically ill patients
undergoing CRRT. However, in cardiac surgery patients
with severe MODS, the adoption of a 12 mmol/l citrate
solution may have the drawback of a suboptimal buffers
supply, easily overwhelmed by bicarbonate supplementa-
tion. In forthcoming studies, our efforts will be focused
on improving the RCA-CVVH protocol to further mini-
mize the need for calcium supplementation and to better
customize buffers balance in the individual patient,
according to acid-base status and through the use of dif-
ferent combinations of citrate solutions and post-dilution
replacement fluids.
Key messages
• RCA-CVVH with a low concentration citrate solu-
tion ensured an adequate filter life and allowed a
decrease in transfusion rates. Furthermore, platelet
count and AT-III activity increased throughout the
RCA-CVVH days.
• RCA was able to limit the discrepancy between
prescribed and delivered dose by minimizing CRRT
downtime.
• During RCA-CVVH, the need for calcium chloride
supplementation may be reduced, in the absence of
venous drip chamber clotting, by the use of a cal-
cium-containing post-dilution replacement solution.
• In cardiac surgery patients undergoing RCA-
CVVH for AKI associated with severe MODS, the
use of a particularly low concentration citrate solu-
tion may be associated with the drawback of a
‘suboptimal’ buffers supply, easily overwhelmed by
bicarbonate supplementation.
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